AIMS: To test autoantibodies from subsets of diabetes with painful neuropathy, maculopathy and nephropathy for effects in neurons. METHODS: Protein-A eluates from plasma of 27 diabetic and 19 age-matched controls were tested for effects on endothelial cell survival, and neurite outgrowth in rat pheochromocytoma PC12 cells. Painful diabetic neuropathy or control autoantibodies were compared for binding to PC12-derived heparan sulfate proteoglycans. The mechanism of the effects from pathologic autoantibodies was investigated by changes in intracellular calcium in endothelial cells, whole cell current in neurons, or using the Rho kinase inhibitor Y27632. RESULTS: Autoantibodies from diabetic patients with maculopathy, nephropathy, and painful neuropathy (n=5) caused significantly greater mean inhibition of neurite outgrowth (p<0.005) than diabetic or control patients with fewer or no complications (n=30). Painful diabetic autoantibodies (3 μg/mL) bound neuronal heparan sulfate proteoglycan (HSPG) more than autoantibodies from diabetic or control subjects without painful neuropathy (p<.0001). Inhibition of PC12 neurite outgrowth by the painful neuropathy antibodies was completely prevented by 1 μM concentrations of Y27632. CONCLUSION: These results suggest anti-endothelial and anti-neuronal effects from auto-antibodies in a subset of diabetic patients with a cluster of microvascular complications. Published by Elsevier Ireland Ltd.
AIMS: To test autoantibodies from subsets of diabetes with painful neuropathy, maculopathy and nephropathy for effects in neurons. METHODS: Protein-A eluates from plasma of 27 diabetic and 19 age-matched controls were tested for effects on endothelial cell survival, and neurite outgrowth in ratpheochromocytoma PC12 cells. Painful diabetic neuropathy or control autoantibodies were compared for binding to PC12-derived heparan sulfate proteoglycans. The mechanism of the effects from pathologic autoantibodies was investigated by changes in intracellular calcium in endothelial cells, whole cell current in neurons, or using the Rho kinase inhibitor Y27632. RESULTS: Autoantibodies from diabeticpatients with maculopathy, nephropathy, and painful neuropathy (n=5) caused significantly greater mean inhibition of neurite outgrowth (p<0.005) than diabetic or control patients with fewer or no complications (n=30). Painful diabetic autoantibodies (3 μg/mL) bound neuronal heparan sulfate proteoglycan (HSPG) more than autoantibodies from diabetic or control subjects without painful neuropathy (p<.0001). Inhibition of PC12 neurite outgrowth by the painful neuropathy antibodies was completely prevented by 1 μM concentrations of Y27632. CONCLUSION: These results suggest anti-endothelial and anti-neuronal effects from auto-antibodies in a subset of diabeticpatients with a cluster of microvascular complications. Published by Elsevier Ireland Ltd.
Authors: Mark B Zimering; N Mirkovic; M Pandya; J H Zimering; J A Behnke; S Thakker-Varia; J Alder; R J Donnelly Journal: J Endocrinol Diabetes Date: 2016-03-08
Authors: Mark B Zimering; Jane H Zhang; Peter D Guarino; Nicholas Emanuele; Peter A McCullough; Linda F Fried Journal: Front Endocrinol (Lausanne) Date: 2014-08-11 Impact factor: 5.555